Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104326 | 0.89 | CYP2A6 (0.64) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL134108 | 0.83 | CYP2A6 (0.53) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL12947816 | 0.81 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL30098437 | 0.81 | ALDH1A1 (0.56) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL22130223 | 0.81 | ALDH1A1 (0.56) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL968383 | 0.81 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL3831923 | 0.81 | CYP2A6 (0.57) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL21410153 | 0.81 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL15455285 | 0.79 | CYP2A6 (0.50) | CYP2A6CYP2B6CYP2E1CYP11B2CYP3A4 | |
| SCHEMBL415945 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889702-B2 | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8865738-B2 | 5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| EP-2393809-B1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| EP-2429998-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
| CN-102459189-A | 5-membered heterocyclic compound cyclopenta [ c ] pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2012-05-16 | — | — | CN | disclosed |
| EP-2429998-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
| EP-2393809-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010130943-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010089510-A2 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | CYP2A6 350/4885CYP2B6 118/4885CYP2E1 794/4885 |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CA9, SCN9A, CCR9 | CYP2A6 978/4885CYP2B6 346/4885CYP2E1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.